%PDF-1.4
%
47 0 obj
<>
endobj
43 0 obj
<>
endobj
104 0 obj
<>stream
Acrobat Distiller 5.0 for Macintosh
2003-02-05T19:26:52Z
2024-03-28T05:30:53-07:00
2024-03-28T05:30:53-07:00
QuarkXPress. 4.11: AdobePS 8.6 (219)
application/pdf
Heather
2002-112.march
uuid:0bad66cd-1dd2-11b2-0a00-bd0927bd3700
uuid:0bad66d0-1dd2-11b2-0a00-5b0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
48 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
126 0 obj
[130 0 R]
endobj
127 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(3.)-875.1 (Reginster JY)128.8 (, Deroisy R, Rovati LC, et al. Long-term ef)17.7 (fects of)]TJ
1.675 -1.25 Td
(glucosamine sulphate on osteoarthritis progression: a randomised,)Tj
0 -1.25 TD
(placebo-controlled clinical trial. Lancet 2001;357:251-6.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Setnikar I, Pertusi R, Canali S, Zanolo G. Pharmacokinetics of)]TJ
1.675 -1.25 Td
[(glucosamine in man. )54.8 (Arzneimittel-Forschung 1993;43:1)36.8 (109-13.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Reichelt )54.8 (A, Forster KK, Fischer M, Rovati LC, Setnikar I. Ef)17.7 (ficacy)]TJ
1.675 -1.25 Td
(and safety of intramuscular glucosamine sulfate in osteoarthritis of)Tj
T*
[(the knee. )54.8 (A)-220.1 (randomised, placebo-controlled, double-blind study)64.8 (.)]TJ
T*
(Arzneimittel-Forschung 1994;44:75-80.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Leeb BF)79.7 (, Schweitwer H, Montag K, Smolen JS. )54.8 (A)-220.1 (metaanalysis of)]TJ
1.675 -1.25 Td
(chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol)Tj
0 Tc 0 Tw T*
[(2000;27:205-1)36.9 (1.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Das )54.8 (A)-220.1 (J)0.2 (r)39.7 (, Hammad )17.7 (T)79.9 (A. Ef)17.7 (ficacy of a combination of FCHG49)]TJ
1.675 -1.25 Td
[(glucosamine hydrochloride, )17.7 (TRH122 low molecular weight sodium)]TJ
T*
(chondroitin sulfate and manganese ascorbate in the management of)Tj
T*
(knee osteoarthritis. Osteoarthritis Cartilage 2000;8:343-50.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Deal CL, Moskowitz R)54.8 (W)91.8 (. Nutraceuticals as therapeutic agents in)]TJ
1.675 -1.25 Td
[(osteoarthritis. )17.7 (The role of glucosamine, chondroitin sulfate, and)]TJ
T*
[(collagen hydrolysate. Rheum Dis Clin North )54.8 (Am 1999;25:379-95.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Ronca G, Conte )54.8 (A. Metabolic fate of partially depolymerized shark)]TJ
1.675 -1.25 Td
(chondroitin sulfate in man. Int J Clin Pharmacol Res 1993;13)Tj
0 Tw T*
(Suppl:27-34.)Tj
0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Hanpanitcharoen M, Brown MB, Martin GP)110.7 (. )17.7 (The role of)]TJ
2.175 -1.25 Td
(glycosaminoglycans on the skin partitioning of ibuprofen. J Pharm)Tj
T*
(Pharmacol 1998;30:183.)Tj
-0.0369 Tc 0 Tw -2.1381 -1.25 Td
[(11)-36.9 (.)]TJ
-0.00011 Tc 0.02499 Tw 2.0881 0 Td
[(Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.9 (.)]TJ
0 Tc 0 Tw 0.05 -1.25 Td
(V)Tj
-0.00011 Tc 0.02499 Tw 0.6111 0 Td
[(alidation study of )17.7 (WOMAC: a health status instrument for)]TJ
-0.6111 -1.25 Td
(measuring clinically important patient relevant outcomes to)Tj
T*
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (McHorney CA, )17.7 (W)79.9 (are JE, Raczek EE. )17.7 (The MOS 36-Item )]TJ
2.175 -1.25 Td
(Short-Form Health Survey \(SF-36\): II. Psychometric and clinical)Tj
T*
(tests of validity in measuring physical and mental health constructs.)Tj
T*
(Med Care 1993;31:247-63.)Tj
30.825 41.25 Td
[(13.)-875.1 (Altman R, )54.8 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
2.175 -1.25 Td
(classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. Diagnostic and )17.7 (Therapeutic Criteria)]TJ
T*
[(Committee of the )54.8 (American Rheumatism )54.8 (Association. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1986;29:1039-49.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (StataCorp. Stata statistical software \(Release 7.0\). College Station,)]TJ
2.175 -1.25 Td
(TX: Stata Corporation; 2001.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Diggle PJ, Liang KY)128.8 (, Zeger SL. )54.8 (Analysis of longitudinal data.)]TJ
2.175 -1.25 Td
(Oxford: Clarendon Press; 1994.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Baltagi BH, )17.7 (W)39.8 (u PX. Unequally spaced panel data regressions with)]TJ
2.175 -1.25 Td
[(AR\(1\) disturbances. Econometric )17.7 (Theory 1999;15:814-23.)]TJ
-2.175 -1.25 Td
[(17.)-875.1 (Bromm B, Scharein E, Darsow U, Ring J. Ef)17.7 (fects of menthol and)]TJ
2.175 -1.25 Td
(cold on histamine-induced itch and skin reactions in man. Neurosci)Tj
T*
(Lett 1995;187:157-60.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Green BG. Sensory characteristics of camphor)54.8 (. J Invest Dermatol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1990;94:662-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Lopes )17.7 (V)128.9 (A. Double-blind clinical evaluation of the relative ef)17.7 (ficacy)]TJ
2.175 -1.25 Td
(of ibuprofen and glucosamine sulphate in the management of)Tj
T*
(osteoarthrosis of the knee in out-patients. Curr Med Res Opin)Tj
0 Tc 0 Tw T*
(1982;8:145-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Lewis B, Lewis D, Cumming G. )17.7 (The comparative analgesic )]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy of transcutaneous electrical nerve stimulation and a )]TJ
T*
(non-steroidal antiinflammatory drug for painful osteoarthritis. Br J)Tj
T*
(Rheumatol 1994;33:455-60.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Houpt JB, McMillan R, )17.6 (W)79.9 (ein C, Paget-Dellio SD. Ef)17.7 (fect of)]TJ
2.175 -1.25 Td
(glucosamine hydrochloride in the treatment of pain of osteoarthritis)Tj
T*
(of the knee. J Rheumatol 1999;26:2423-30.)Tj
ET
0 0 0 0 scn
418 777 139 -27 re
f
BT
0 0 0 1 scn
/T1_1 1 Tf
0 Tc 0 Tw 20.37 0 0 21 462.082 760.6089 Tm
[(2002-1)54.9 (12-6)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(528)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
61 0 obj
<>
endobj
52 0 obj
<>
endobj
50 0 obj
<>
endobj
91 0 obj
<>
endobj
109 0 obj
<>
endobj
51 0 obj
<>
endobj
86 0 obj
<>stream
HTkPSgpKvʩEk+҂VRE@"X\"D@. @@2PעQY[vyg|;<ڊaSHPh`qb:?-brUOX1nKtWᯟ Y
ni
,&%OoK$!3,0QKit]-x\WhN^F0-8H3bII'flieO$|d0Kl1R+=bwجI&9amV K˚`c`oVVWpW\['Z7Y$~boeOli'B."E,[L/.~$oҀKl)v?tqsSV99=VQW;/oYKJWCCsD(JP~g~Ss`pi츩Vz!,5z3HJy}8DP:Yeu إ.Erh-E
]'GO
<!=CK~9PgzBьf>P.)R&
NBQL&KAtBٻ!͡ؽy %0tuL]]9& 'G0Zåݨ-jg9y49ЛЕ;¿V3`h4wXBG`uz'ٗGM^ZeTԸgOȑ"sUYkT͞yX Ya@iQh
nA^R^)rG J&)GWuJΩipf5
ء4b.Jf7|Vȴ[YS&=2"UMV]U48o8EGAFK06,w@0cpa^RͭCmK[f+riyHtz"Ei4_])?Or(KciPTV*VT)>;\YӘ #lXXńř4enMnNӿx_g1:3mԂQ ) V@
Hg@idɄ(r!B9lG6\`;I2{RH~IaUlU_m'ZR,ej( 尣ꠖ.t0n_'xRʰͽ}evt`aN7"WW_|jJ9pO`5*j%ZDВHOV07M{DqDp}^gI_?Fd,,Jo%9r#r.يV6Ζwa//ḽ!8%f639-&/;
67C:6|Gn^1J\H=M:mikoH%_'̣prmDLӧ&Çk>ݟ/M+Ia2;gϾy/nL`pGԋoA1y|